BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 15956649)

  • 1. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
    Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
    J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Cappuzzo F
    J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
    Ermoian RP; Furniss CS; Lamborn KR; Basila D; Berger MS; Gottschalk AR; Nicholas MK; Stokoe D; Haas-Kogan DA
    Clin Cancer Res; 2002 May; 8(5):1100-6. PubMed ID: 12006525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
    Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
    Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
    Wick W; Furnari FB; Naumann U; Cavenee WK; Weller M
    Oncogene; 1999 Jul; 18(27):3936-43. PubMed ID: 10435616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
    Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
    Fan QW; Cheng CK; Nicolaides TP; Hackett CS; Knight ZA; Shokat KM; Weiss WA
    Cancer Res; 2007 Sep; 67(17):7960-5. PubMed ID: 17804702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
    Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
    Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
    Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
    Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
    Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
    J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.